Biomedical or Dental Material
AstraZeneca Invests $2 Billion in CSPC’s Lipid-Lowering Therapy
AstraZeneca, CSPC Pharmaceutical Group, lipid-lowering therapy, Lp(a) disruptor, cardiovascular disease, pharmaceutical investment
Johnson & Johnson Abandons 340B Rebate Plan Following HRSA Pressure and Congressional Advocacy
340B drug discount program, Johnson & Johnson, HRSA, rebate model, healthcare policy, pharmaceutical pricing
Avadel Pharmaceuticals’ Narcolepsy Drug LUMRYZ Receives FDA Approval and Orphan Drug Exclusivity
Avadel Pharmaceuticals, LUMRYZ, narcolepsy, FDA approval, Orphan Drug Exclusivity, sodium oxybate, extended-release oral suspension
Catalent Reports Strong Q4 Results Amid Pending Acquisition by Novo Holdings
Catalent, Q4 Results, Novo Holdings, Acquisition, Pharmaceutical, Biotech, Consumer Health
Ovid Halts Preclinical Work and IV Seizure Program Following Soticlestat’s Phase 3 Setbacks
Ovid Therapeutics, soticlestat, Phase 3 trials, Dravet syndrome, Lennox-Gastaut syndrome, preclinical work, IV seizure program, Takeda Pharmaceutical
Bristol Myers Squibb Terminates $1.6 Billion Deal, Returns TIGIT Rights to Agenus
Bristol Myers Squibb, Agenus, TIGIT, licensing agreement, pharmaceutical deal
Otsuka Pharmaceutical Acquires Jnana Therapeutics for $800M to Develop PKU Treatment
Otsuka Pharmaceutical, Jnana Therapeutics, PKU, phenylketonuria, JNT-517, RAPID chemoproteomics platform, rare metabolic disorder, biotech acquisition
President Biden Highlights Achievements in Lowering Prescription Drug Costs as He Steps Down from Re-election Campaign
President Biden, drug pricing, re-election campaign, Medicare, Inflation Reduction Act, prescription drug costs, health care costs, pharmaceutical industry
Novartis Partners with Dren Bio in $3 Billion Deal for Targeted Myeloid Engagers
Novartis, Dren Bio, Myeloid Engagers, Biotech, Pharmaceutical, Alliance, $3 Billion Deal
Ionis Advances to Phase 3 Trial for Angelman Syndrome Treatment ION582
Ionis Pharmaceuticals, Angelman syndrome, ION582, Phase 3 trial, antisense oligonucleotides, neurological conditions, rare diseases, Biogen, Ultragenyx Pharmaceutical